Citations

Clear

5 citation(s) found for "Reddy, Sunil".

Efficient Separation of Related Substances in Clidinium Bromide and Chlordiazepoxide Hydrochloride Capsules using Reversed-phase Ultra-performance Liquid Chromatography
Kumar, Garimi Tirumala Jyothesh, Andrews, B. S. A. , Reddy, P. Sunil, Venugopal, Nutulapati V.S. , Vijayalakshmi, Kancharla , Abbaraju, V D N Kumar

Mayo Clinic

Research Journal of Pharmacy and Technology | April 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: 372-378

10.52711/0974-360x.2025.00058 Get It

A validated reverse-phase ultra-performance liquid chromatography (UPLC) method has been developed for the precise determination of impurities in Clidinium Bromide (CDB) and Chlordiazepoxide Hydrochloride (CDH) Capsules. This study focuses on the separation of impurities, namely Benzylic acid (BZY) related to Clidinium, Chlordiazepoxide Related Compound A (CDRC-A), and Chlordiazepoxide Related Compound C (CDRC-C). The Water’s H-Class UPLC system, equipped with a PDA Detector, was employed with a 15µL loop size, operating at a detection wavelength of 215 nm in gradient mode with a flow rate of 0.3 mL/min, resulting in a total run time of 55 min. The chromatographic separation utilized a Waters Acquity UPLC BEH C18 column (150 mm × 2.1 mm i.d., 1.7 µm particle size) at a column temperature of 55°C. The method demonstrated robustness and accuracy with retention times for CDB (4.4), BZY (5.2), CDRC-A (8.5), CDH (12.1), and CDRC-C (33.8). The % Accuracy at 100% for CDB is 98.2, BZY is 0.0765, CDRC-A is 0.1350, CDH is 98.2 and CDRC-C is 101.0 respectively. LOQ values for CDB is 0.0756, BZY is 0.0765, CDRC-A is 0.1464, CDH is 0.0749 and CDRC-C is 0.1932. Linear responses were observed for all impurities, including CDB and CDH. This validated UPLC method is deemed more appropriate to regular QC analysis as well as Stability study analysis of CDB and CDH Capsules formulations.
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Zaid, Mohammad Abu , Achufusi, Amaka, Armand, Philippe , Bermas, Bonnie L. , Braaten, Tawnie , Chokshi, Saurin , Crees, Zachary , Davies, Marianne, Deng, Changchun , Gesthalter, Yaron , Jallouk, Andrew , Khalil, Maya, Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Patel, Sandip Pravin , Prosek, Jason, Reddy, Sunil , Reid, Pankti , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Zucker, Stephen D. , Lyons, Megan , Hang, Lisa, Ryder, Mabel , Berkenstock, Meghan , Bermas, Bonnie , Budde, Lihua E. , Jain, Michael D. , Jain, Prantesh , Kaffenberger, B , Lechner, Melissa G , Li, Tianhong , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Oluwole, Olalekan O. , Ryan, John, Salman, Huda , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G , Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 13, 2024 | Volume: 22 | Issue: 9 | Pages: 582-592

10.6004/jnccn.2024.0057 | PMID 39536465 Get It

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Achufusi, Amaka, Armand, Philippe , Bhatia, Shailender , Chokshi, Saurin , Davies, Marianne, Elshoury, Amro, Gesthalter, Yaron , Kaffenberger, Benjamin H. , Li, Tianhong , Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Oluwole, Olalekan O. , Patel, Sandip Pravin , Patil, Pradnya D. , Reddy, Sunil , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Lyons, Megan , Dwyer, Mary A., Hang, Lisa, Oluwole, Olalekan O , Kaffenberger, B , Ryder, Mabel , Berkenstock, Meghan , Budde, Lihua E. , Hegde, Aparna , Jain, Michael D. , Lechner, Melissa G , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 7, 2022 | Volume: 20 | Issue: 4 | Pages: 387-405

10.6004/jnccn.2022.0020 | PMID 35390769 Get It

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visitNCCN.org.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Andrews, Stephanie, Armand, Philippe , Davies, Marianne, Dunnington, David, Frigault, Matthew J. , Kaffenberger, Benjamin H. , Lunning, Matthew A. , McGettigan, Suzanne , McPherson, Jordan P. , Mohindra, Nisha , Naidoo, Jarushka , Olszanski, Anthony J. , Oluwole, Olalekan O. , Patel, Sandip Pravin , Reddy, Sunil , Ryder, Mabel , Santomasso, Bianca , Shofer, Scott , Sosman, Jeffrey A. , Weight, Ryan , Johnson-Chilla, Alyse, Zuccarino-Catania, Griselda, Engh, Anita M. , Oluwole, Olalekan O , Naidoo, Jarushka , Olszanski, Anthony J , Kaffenberger, B , Ryder, Mabel , Bhatia, Shailender , Budde, Lihua E. , Costa, Luciano J. , Ernstoff, Marc S. , Pennell, Nathan A , Wang, Yinghong

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 5, 2020 | Volume: 18 | Issue: 3 | Pages: 230-241

10.6004/jnccn.2020.0012 | PMID 32135517 Get It

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Andrews, Stephanie, Armand, Philippe , Davies, Marianne, Dunnington, David, Frigault, Matthew J. , Hoffner, Brianna, Lunning, Matthew A. , Mohindra, Nisha , Naidoo, Jarushka , Olszanski, Anthony J. , Oluwole, Olalekan O. , Patel, Sandip Pravin , Reddy, Sunil , Ryder, Mabel , Santomasso, Bianca , Shofer, Scott , Sosman, Jeffrey A. , Wahidi, Momen M. , Johnson-Chilla, Alyse, Scavone, Jillian L., Oluwole, Olalekan O , Naidoo, Jarushka , Olszanski, Anthony J , Ryder, Mabel , Bhatia, Shailender , Budde, Lihua E. , Costa, Luciano J. , Ernstoff, Marc S. , Hoimes, Christopher , Lacouture, Mario E. , Locke, Frederick L. , Wang, Yinghong

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 20, 2019 | Volume: 17 | Issue: 3 | Pages: 255-289

10.6004/jnccn.2019.0013 | PMID 30865922 Get It

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org .